Results of the present study implied the roles of EGFR/MAP2K1/mTOR/YAP1 signaling pathways in the progression, therapeutic resistance, immune-invasive phenotypes, and worse prognoses of NSCLC. This evidence concerns the gene MAP2K1 and non-small cell lung carcinoma.